stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Operating cash flow
Denali Therapeutics Inc.'s operating cash flow for fiscal 2025 was −$412.6M, compared with −$347.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$444.2M. Over the past ten years it has ranged from −$412.6M (fiscal 2025) to $416.2M (fiscal 2020) — the current reading is the lowest in ten years. Denali Therapeutics Inc. ranks 588th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$412.6M | — |
| FY2024 | −$347.7M | — |
| FY2023 | −$358.0M | — |
| FY2022 | −$244.7M | — |
| FY2021 | −$211.4M | — |
| FY2020 | $416.2M | — |
| FY2019 | −$151.6M | — |
| FY2018 | $50.1M | — |
| FY2017 | −$76.6M | — |
| FY2016 | −$71.9M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$117.4M | — |
| Jun 2026 | −$97.0M | — |
| Mar 2026 | −$131.2M | — |
| Dec 2025 | −$98.5M | — |
| 37 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | $51.9M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $49.9M |
| ELVN Enliven Therapeutics, Inc. compare | −$66.9M |
| CELC Celcuity, Inc. compare | −$191.7M |
| VRDN Viridian Therapeutics, Inc. compare | −$341.5M |
| IDYA IDEAYA Biosciences, Inc. compare | −$347.4M |
| DNLI Denali Therapeutics Inc. | −$444.2M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
| DYN Dyne Therapeutics, Inc. compare | −$477.8M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement